Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag in Treatment-Naive Severe Aplastic Anemia
NCT03825744Phase 3Completed
- Sponsor
- Hengrui
- Start
- Mar 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in aplastic anemia comparing Hetrombopag + Standard Therapy with Placebo + Standard Therapy (2 arms). Primary endpoint: Rate of complete hematologic response at 6 months. Started Mar 2019; status: completed.
02
Drugs
hetrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT03825744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825744.